Corrigendum to "Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy" [Eur. J. Pharm. Sci. 111 (1 January 2018) 492-502].

Guirong Zheng Ruirui Zhao Aixiao Xu Zhichun Shen Xian Chen Jingwei Shao

Eur J Pharm Sci

Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116, China. Electronic address:

Published: March 2018

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.ejps.2018.01.012	DOI Listing

Publication Analysis

Top Keywords

corrigendum "co-delivery

"co-delivery sorafenib

sorafenib sivegf

sivegf based

based mesoporous

mesoporous silica

silica nanoparticles

nanoparticles asgpr

asgpr mediated

mediated targeted

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!